Purchase this article with an account.
R. Adam, T. Rodallec, J.P. Nordmann; Indometacine and Macular Thickness Undergoing Cataract Surgery: A Prospective Randomized Study . Invest. Ophthalmol. Vis. Sci. 2005;46(13):787.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose:To compare macular thickness before and after phacoemulsification with or without indometacine therapy. Methods: 50 eyes of 42 patients scheduled for phacoemulsification were randomly assigned to take indometacine and tobramycin–dexamethasone as postoperative therapy (groupe 1 =25), or to take only tobramycin–dexamethasone (groupe 2 =25). All eyes underwent optical coherence tomography (OCT) the day before, one week and one month after surgery. Complicated surgeries were excluded. Moreover all patients were free of all other pathology. OCT examination and interpretation were done by an expert masked for treatment and exam timing. Five OCT fast macular maps were done each time. Patients with artifacted OCT images were excluded. Results: All randomized eyes undergone successful phacoemulsification with in the bag IOL implantation were included in the analysis. No significant preoperative difference was detected between the two groups for age, visual acuity and macular thickness (200.1±10.9µm vs 190±4.28µm). Macular thickness was 202.5±11.6µm vs 194.6±5.47µm at one week and 198±11.1µm vs 192±6.25µm at one month. That was not statistically significant difference at one week (p=0,59)and one month(p=0.55). Conclusions: No significant difference was found between the two groups of macular thickness. Larger investigations might be done to evaluate macular thickness for complicated cataract surgery and for diabetic patients. It would be very interesting to know anti–inflammatory drug action also in the patient group where we failed to do OCT exam befor operation because of reduced transparency due to cataract.
This PDF is available to Subscribers Only